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AbstrAct
Temporomandibular disorders (TMD) include cra-
niocervical pain conditions with unclear etiolo-
gies. Central changes are suspected; however, few 
neuroimaging studies of TMD exist. Single-voxel 
proton magnetic resonance spectroscopy (1H-
MRS) was used before and after pressure-pain 
testing to assess glutamate (Glu), glutamine (Gln), 
N-acetylaspartate (NAA), and choline (Cho) levels 
in the right and left posterior insulae of 11 indi-
viduals with myofascial TMD and 11 matched 
control individuals. Glu levels were significantly 
lower in all individuals after pain testing. Among 
those with TMD, left-insular Gln levels were 
related to reported pain, left posterior insular NAA 
and Cho levels were significantly higher at base-
line than in control individuals, and NAA levels 
were significantly correlated with pain-symptom 
duration, suggesting adaptive changes. The results 
suggest that significant central cellular and molec-
ular changes can occur in individuals with TMD.
KEY WOrDs: magnetic resonance spectros-
copy, temporomandibular disorders, N-acetyl 
aspartate, choline, glutamate, glutamine.
IntrODuctIOn
temporomandibular disorders (TMD) are musculoskeletal conditions often characterized by pain in the temporomandibular joints and/or mastica-
tory muscles. The prevalence of the myofascial subtype of TMD, as defined 
by the Research Diagnostic Criteria (RDC), is ~10.5% (Janal et al., 2008). 
Prevalence is higher among younger women; white and non-white ethnicities 
suffer similar prevalence rates (Janal et al., 2008).
TMD etiologies and pathophysiologies are poorly understood. Current 
models have been described as inadequate and lacking an appreciation of the 
neural basis of chronic pain (Greene, 2001). Only recently have investigators 
begun using neuroimaging to study the central processing of trigeminal 
myogenous pain (e.g., Nash et al., 2010a,b).
The insula is involved with central pain processing (reviewed in Peyron 
et al., 2000). The posterior insula is one of the few cortical sites where electri-
cal stimulation can elicit disabling muscle-pain or headache sensations 
(Ostrowsky et al., 2002; Mazzola et al., 2009). A somatotopic representation 
exists in the posterior insula, with the face being represented rostrosuperiorly 
to the body’s representation (Ostrowsky et al., 2002; Brooks et al., 2005). 
Facial pain may be represented in the contralateral (Coghill et al., 2001), 
bilateral (Jantsch et al., 2005), or combinations of contralateral, ipsilateral, 
and bilateral insulae (Ostrowsky et al., 2002; Mazzola et al., 2009). Patients 
with posterior insular infarcts manifest faciobrachiocrural impairments of 
elementary sensations, including pain (Cereda et al., 2002).
Recent work has demonstrated insular neurochemical changes in fibromyal-
gia (FM) (Gracely et al., 2002; Harris et al., 2008, 2009), which is why we 
focused on this brain region. We used proton magnetic resonance spectroscopy 
(1H-MRS) to investigate cellular and molecular activity within the posterior 
insulae of individuals with TMD and healthy control (HC) individuals. 1H-
MRS, a magnetic resonance imaging (MRI) procedure, measures metabolite 
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levels within pre-defined voxels (Ross and Bluml, 2001; Novotny 
et al., 2003).
We evaluated glutamate (Glu), glutamine (Gln), their combi-
nation (Glx = Glu + Gln), N-acetylaspartate (NAA), and choline 
(Cho) levels. Glu is a major cortical neurotransmitter implicated 
in negative affect related to pain (Mullins et al., 2005). Gln is a 
metabolite of Glu; together, Glu and Gln participate in complex 
metabolic activity cycles and intercellular communication 
involving neurons and astrocytes (Yang et al., 2008). NAA is a 
biomarker of neuronal health and of neuronal and axonal num-
bers (Ross and Bluml, 2001; Gujar et al., 2005). Cho is associ-
ated with increased cell numbers, membrane synthesis, and/or 
membrane breakdown, e.g., demyelination, malignancies (Gujar 
et al., 2005). These biomarkers provide important information 
about the health and condition of brain activity.
MAtErIAls & MEthODs
study Population
Twenty-two right-handed individuals were screened and recruited, 
including 11 with TMD and 11 healthy individuals (HC) carefully 
pair-wise-matched for gender (one male, 10 females per group), 
age (TMD mean ± SD = 25.8 ± 2.33 vs. HC 24.8 ± 1.20), and 
ethnicity (seven White, three Asian-American, one African-
American per group). Because symptoms are not ethnicity- 
specific (Janal et al., 2008), we recruited according to local ethnic 
demographics of Washtenaw County, Michigan. All participants 
gave written informed consent; protocols were approved by the 
University of Michigan Medical Institutional Review Board.
TMD-group inclusion criteria were based on RDC-Group 1 
criteria (Dworkin and LeResche, 1992), i.e., presence of ongoing 
pain involving ≥ 3 tender muscle sites ipsilateral to palpation pain. 
HC-group inclusion criteria included < 3 tender muscle sites and 
no history of chronic pain. Selected TMD 
individuals had bilateral symptoms in the 
masseter (N = 7), temporalis (N = 1), 
masseters and temporalis (N = 2), or right 
masseter only (N = 1). None had joint 
involvement (RDC, Groups 2, 3). 
Exclusion criteria for both groups were 
pre-existing medical or outstanding den-
tal conditions, history of arthritis, heart 
conditions, diabetes, migraine, tension 
headache, back pain, tooth pain, FM, 
schizophrenia, use of pain medications 
within the previous 2 wks, medications 
with central or peripheral neural actions, 
bite splints, or current TMD treatments.
Because TMD symptoms vary with 
menstrual phase (LeResche et al., 2003), 
female participants were scheduled for 
appointments between days 1 and 3 of 
menses.
study Procedure
Participants underwent screening, a 
physical examination, and an orofacial 
examination assessing range of motion, occlusion, TMJ noises, 
orofacial motor strength, facial sensory status, and RDC exami-
nation procedures (Dworkin and LeResche, 1992). Psychometric 
tests were used to screen for psychiatric illness. The McGill pain 
questionnaire short form (MPQ-SF) and the State-Trait 
Personality Inventory (STPI) were identified a priori for use in 
analyses.
On a 2nd day, pressure-pain testing was performed on the 
right thumbnail bed (thumb test) and then on the right anterior 
temporalis (head test). Pressures, applied with a 1-cm rubber 
syringe and customized pneumatic system, were ramped to a 
pre-selected pressure in 1 sec, held for 5 sec, and then released. 
Pressure applications recurred every 25 sec.
An ascending-staircase followed by a multiple random-staircase 
technique identified pressures that elicited subjective responses of 
mild (3/20), moderate (11/20), and severe (15/20) pain ratings on a 
Box Scale (Gracely et al., 1988). Pressures eliciting mild, moder-
ate, and severe pain responses were used in day-3 tests.
On day 3, T1 anatomical images were used to locate the 
voxels of interest (VOI) for the 1H-MRS procedures. Single-
voxel 1H-MRS (3T, GE Signa MRI scanner, Milwaukee, WI, 
USA) was performed on posterior insular cortices before pain-
testing (pre-pain test or “Pre”, Fig. 1A). Next, pressure-pain 
testing was performed in conjunction with another study; 
25-second painful pressures were applied followed by 25-sec-
ond rest periods. Twelve pressure-rest blocks were given on the 
left thumb and then on the left anterior temporalis. Immediately 
thereafter, single-voxel 1H-MRS was again performed in poste-
rior insular cortices (post-pain test or “Post”, Fig. 1A).
Imaging Protocol
The protocol (Fig. 1A) included standard T1 structural images, 
and 4 single-voxel 1H-MRS sequences with point-resolved 
Figure 1. (A) Scanning session protocol. Pre = Pre-pain test 1H-MRS runs; Post = post-pain test 
1H-MRS runs of left (LPI) followed by right (RPI) posterior insula. Each run lasted ~ 8 min. The 
pain-testing study (fMRI) lasted ~ 20 min. (b) Voxel placement in RPI. (c) Spectrum and fitted 
LC-model for one participant.
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spectroscopy (PRESS; TR = 3000 ms, TE = 30 ms, 90-degree 
flip angle, NEX 8, FOV 16 cm, VOI = 2 × 2 × 3 cm) placed in 
the left and then right posterior insula (Fig. 1B) pre- and post-
pain testing. 1H-MRS data were analyzed by a neuroradiologist 
blinded to participant group membership and using a linear 
combination of individual spectra obtained from pure molecular 
species to fit the experimental spectra (LCModel; Oakville, ON, 
Canada; Fig. 1C). Metabolite levels were calculated as absolute 
concentrations, normalized to the water signal and reported in 
arbitrary institutional units.
statistical Analysis
A mixed-effect repeated-measures design analysis of variance 
(ANOVA) (SAS, ver. 9.2) was used to analyze group differences 
in Glu, Gln, and Glx metabolite concentrations. Side (left vs. 
right), time (pre- vs. post-pain testing), group (HC vs. TMD), and 
participant pairs (11 pairs) were treated as fixed effects; each 
participant was treated as a random effect. The model also evalu-
ated group x time and group x side interactions. Because NAA 
and Cho probably represent long-term effects, only pre-pain-
testing concentrations of these metabolites were tested (paired t 
test using matched TMD-HC participants for pairing). Each TMD 
participant was matched to a specific HC participant for age, 
gender, and ethnicity, to control for demographic heterogeneities, 
thus allowing for a broader demographic to be used within a small 
study design.
Correlation analyses were performed to assess the degree of 
association between TMD-group metabolite levels and both 
MPQ-SF and STPI psychometric scores. Pearson’s product 
moment correlation coefficient, r, was used for continuous, nor-
mally distributed variables. All other correlations used 
Spearman’s rank correlation method, ρ. A p < 0.05 defined sta-
tistical significance.
rEsults
TMD mean pain severity scores = 3.8/10 (SD = 2.2) on screening 
day. Symptom histories ranged from 6 mos to 7 yrs. HC pain sever-
ity scores = 0/10 (SD = 0), with no history of TMD symptoms.
The Table shows individual-group mean (1 SD) pre- and post-
pain test concentrations in left and right insulae for Glu, Gln, and 
Glx. Only pre-test levels appear for NAA and Cho (see Materials 
& Methods). Tabled values do not reflect within-individual or 
paired-individual differences, which are detailed below.
Controlling for participant group, Glu levels significantly 
decreased pre- to post-pain testing within-participants (F[1,61] 
= 6.04, p = 0.0168, Fig. 2). Glu levels were higher in the left vs. 
right insulae within participants (F[1,61] = 4.14, p = 0.0462). No 
significant Glu-level differences existed between groups.
A significant interaction between side and group occurred for 
Gln (F[1,61] = 4.64, p = 0.0353, Fig. 2). TMD-group Gln levels 
were significantly higher in the right vs. left insula (t = -3.83, p 
= 0.0003). HC-group Gln levels did not differ by side (t = -0.76, 
p = 0.45). Right insular Gln levels were higher in TMD vs. HC 
(t = -3.16, df = 61, p = 0.0025). Between-group differences in 
left insular Gln levels were not significant (t = -0.62, p = 0.54). 
No significant between-group differences in Gln existed pre- vs. 
post-pain testing, nor were any differences observed involving 
Glx.
Left insular Gln levels of TMD participants in the pre-test 
condition were negatively correlated with visual analog scale 
(VAS) scores of present pain level (r = -0.78; df = 9, p = 0.005), 
MPQ sensory scale (ρ = -0.81, df = 9, p = 0.001), affective scale 
(ρ = -0.67, df = 9, p = 0.02), and total pain scores (ρ = -0.88, df 
= 9, p < 0.001). Left insular Glx levels, pre-test, were signifi-
cantly correlated with VAS pain (r = -0.79; p = 0.004), MPQ 
sensory (ρ = -0.714; p = 0.014), and MPQ total pain (ρ = 
-0.662; p = 0.026) scores, but not with MPQ affective pain 
(ρ = -0.469; p = 0.146).
Left insular NAA (t = 2.33, df = 21, p = 0.030; Fig. 3, top) 
and Cho levels (t = 2.25, df = 21, p = 0.036; Fig. 3, middle) were 
significantly higher in TMD vs. HC participants. Left insular 
NAA levels were positively correlated with pain symptom dura-
tion in participants with TMD (r = 0.761, df = 9, p = 0.0066; Fig. 
3). No significant between-group differences or significant cor-
relations with psychometric scores were observed involving 
right insular NAA or Cho.
DIscussIOn
This study provides the first evidence of central cellular and 
molecular alterations in myofascial-type TMD. Recent work has 
demonstrated cellular and molecular alterations in the posterior 
table. Mean (± SD) Metabolite Levels
HC TMD
Metabolite Trial Left Right Left Right
Glu Pre 7.99 (0.54) 7.91 (0.66) 8.05 (0.54) 7.76 (0.94)
 Post 7.83 (0.88) 7.70 (0.69) 7.64 (0.57) 7.23 (0.88)
Gln Pre 3.14 (1.38) 3.16 (1.55) 3.62 (0.86) 4.48 (1.00)
 Post 3.40 (1.11) 3.79 (1.13) 3.40 (0.89) 4.64 (1.31)
Glx Pre 11.13 (1.55) 11.07 (1.46) 11.67 (0.87) 12.24 (0.91)
 Post 11.23 (1.38) 11.49 (1.28) 11.05 (1.13) 11.87 (1.51)
NAA Pre 9.81 (0.36) 9.72 (0.40) 10.30 (0.60) 9.88 (0.64)
Cho Pre 1.35 (0.43) 1.40 (0.37) 1.65 (0.13) 1.55 (0.11)
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insula of persons with FM (Harris et al., 2009). However, dis-
tinctions exist between our results and those from the FM study.
For example, right insular Gln levels were elevated in TMD 
vs. HC individuals; no such differences were reported in FM vs. 
HC individuals (Harris et al., 2009). Conversely, we found no 
differences in Glu levels between TMD and HC participants, 
whereas insular Glu levels were elevated in FM vs. HC indi-
viduals (Harris et al., 2009). Nevertheless, Gln levels tended to 
be higher in FM vs. HC individuals, albeit not significantly (p = 
0.13) (Harris et al., 2009).
Insular Glx levels were significantly higher in FM vs. HC 
individuals (Harris et al., 2009). Although Glx levels were not 
significantly different between our TMD and HC participants, a 
tendency existed for Glx to be higher in those with TMD during 
the pre-test condition (Table). Finally, we reported significant 
elevations involving NAA and Cho in participants with TMD. No 
such elevations occurred in persons with FM (Harris et al., 2009); 
however, insular NAA levels tended to be higher in those with 
FM (p = 0.06) (Harris et al., 2009). Conversely, Cho levels tended 
to be lower in those with FM (p = 0.15) (Harris et al., 2009).
Several potential reasons for the differences between FM and 
TMD exist. First, our head-based pressure-pain testing was not 
used on participants with FM. Also, TMD symptoms were 
restricted to the head and neck, whereas FM symptoms occur in 
numerous limb and trunk sites. Such symptomatic differences 
would likely reflect central differences.
Also, although the LCModel is considered capable of resolv-
ing Glu and Gln at 3T, limitations and caveats remain (for 
review, see Ross and Bluml, 2001; Panigrahy et al., 2010). Glu 
and Gln are involved in complex transport, storage, and meta-
bolic cycles among neurons, astrocytes, and glial cells (Shen 
et al., 1999; Gujar et al., 2005; Yang et al., 2008; Panigrahy 
et al., 2010). 1H-MRS cannot distinguish among metabolite 
concentrations related to different molecular pathways or cell 
types. Nevertheless, both individuals with FM and those with 
Figure 2. (top) Mean (± SD) levels for Glu (pooled across participants 
and brain side). (bottom) Interaction between side and group for Gln; 
solid line = TMD, dotted line = HC.
Figure 3. Mean left posterior insular levels of NAA (top) and choline 
(middle), pre-test condition. Correlation between NAA in the LPI and 
symptom duration in TMD (bottom).
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TMD apparently manifest individual-group specific changes in 
posterior insular Glx cycle constituents.
Finally, our TMD participants’ ages averaged 25.8 ± 2.33 yrs, 
whereas the FM study’s participants averaged 45.2 ± 15.0. NAA 
levels are significantly lower and Cho levels higher in over-40 
populations compared with young adults, possibly reflecting 
reduced neuronal viability or function, accelerated membrane 
degradation, or increased glial cell numbers in older individuals 
(Angelie et al., 2001).
Our head and thumb pressure-pain testing procedures may 
have depleted Glu levels, leading to the post-testing reduction in 
Glu manifest by both groups (Fig. 2). Future studies should 
determine whether pain-application duration affects Glu meta-
bolic pathways, which could suggest potential pain ‘chronifica-
tion’ mechanisms.
Because NAA is high in neurons and axons (Panigrahy et al., 
2010), increased left insular NAA levels in our TMD partici-
pants may reflect neuronal or axonal proliferation in response to 
pain symptoms. Four lines of evidence support this possibility. 
First, trigeminal sensory processing, including experimental 
dental pain, occurs in a region contiguous with the posterior 
insula (Becerra et al., 2006; Ettlin et al., 2009), suggesting that 
persistent pain could affect this region. Second, individuals with 
TMD manifest increased white matter volume in a region near 
the left posterior insula (Gerstner et al., 2009). Third, the sig-
nificant positive correlation between left insular NAA levels and 
symptom duration (Fig. 3) suggests a time-dependent increase 
in neuronal processes. Finally, Cho levels were elevated in this 
region (Fig. 3), and Cho is a marker of active membrane metab-
olism in conditions involving increased cell and membrane 
synthesis and membrane degradation, e.g., demyelination, 
malignancies (Gujar et al., 2005). Together, these results suggest 
that our TMD participants’ symptoms may have led to neuronal 
or axonal proliferative changes in the left posterior insula.
Pre-pain, left-insular Gln in TMD participants was nega-
tively correlated with VAS (r = -0.777; p = 0.005), MPQ sensory 
(ρ = -0.811; p = 0.002), affective (ρ = -0.673; p = 0.023), and 
total (ρ = -0.876; p < 0.001) pain scores. Conversely, Glu and 
Glx levels correlated negatively with pressure pain thresholds in 
participants with FM and HC participants (Harris et al., 2009). 
Hence, Gln appears to have been involved with the experience 
of clinical pain in our study, and with the experience of evoked 
pain in the FM study.
The reason for the left-right insular differences reported in our 
study are unclear. Studies indicate that pain testing affects mainly 
the contralateral posterior insula (Brooks et al., 2005), suggesting 
that our asymmetric pressure-pain tests performed on day 2 or 
during scanning may have played a role. Acute pain studies dem-
onstrate that central effects from painful stimuli may outlast pain 
reports (Nash et al., 2011b); hence, our pain testing may have 
caused residual asymmetric central changes that affected our 1H-
MRS results without affecting pain reports. Alternatively, given 
that left and right insular cortices manifest some asymmetric 
functions (Cereda et al., 2002), underappreciated neurochemical 
asymmetries may exist with respect to pain processing.
Our sample size was limited (however, cf. Newberg et al., 
2011), although great care was taken to match participant pairs 
between groups. Larger studies must confirm these results, 
determine whether our pain tests affected the results, and deter-
mine whether the results are clinically significant. Metabolite 
levels in other pain-processing regions will need to be studied as 
well.
Finally, our TMD participants had relatively “normal” pain 
thresholds and relatively minor clinical pain (~3/10 average), 
suggesting that they represented a pain-tolerant TMD phenotype 
(Pfau et al., 2009). Future investigations will need to study the 
relationship between pain phenotype and insular metabolite 
levels.
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